WO2024028902 - ORAL FORMULATIONS OF ABIRATERONE ACETATE AND METHOD OF MANUFACTURING THEREOF
National phase entry:
Publication Number
WO/2024/028902
Publication Date
08.02.2024
International Application No.
PCT/IN2023/050753
International Filing Date
05.08.2023
Title **
[English]
ORAL FORMULATIONS OF ABIRATERONE ACETATE AND METHOD OF MANUFACTURING THEREOF
[French]
FORMULATIONS ORALES D'ACÉTATE D'ABIRATÉRONE ET LEUR PROCÉDÉ DE FABRICATION
Applicants **
BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED
Inventors
DHARMESH MAHENDRABHAI, Shah
ARAVIND MANAPPA, Badiger
MUKESHKUMAR SUBHASHCHANDRA, Sharma
MADHAVKUMAR DILIPBHAI, Trivedi
SAMIRKUMAR BABULAL, Panchal
NILAY MANIKANT, Jayaswal
AKSHAYKUMAR SAMPATSINH, Jadav
Priority Data
202221044843
05.08.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1958 | |
| EPO | Filing, Examination, Granting | 11551 | |
| Japan | Filing, Examination, Granting | 1937 | |
| South Korea | Filing, Examination, Granting | 1669 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,855
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to oral suspension dosage form of Abiraterone Acetate. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing dosage form. Moreover, the solubility and stability of the patient compliant Abiraterone Acetate formulation, prepared as per the present invention, is proven higher when compared to prior art inventions. Furthermore, the present invention also provides a suspension composition prepared by a process which is relatively simple, easy to commercially manufacture, and functionally reproducible.[French]
La présente invention concerne une forme galénique de suspension orale d'acétate d'abiratérone. L'invention concerne également la fourniture d'une forme galénique adaptée au patient, économique et techniquement avancée par rapport à une forme galénique existante. De plus, la solubilité et la stabilité de la formulation d'acétate d'abiratérone adaptée au patient, préparée selon la présente invention, s'avère être plus élevée par rapport aux inventions de l'état de la technique. En outre, la présente invention concerne également une composition de suspension préparée selon un procédé qui est relativement simple, facile à mettre en oeuvre dans le commerce, et fonctionnellement reproductible.